Locus Cell opened Asia's largest cell mass-production facility for regenerative medicine in Hsinchu County, Taiwan, on May 1, 2026 [1, 2].

The opening of the facility marks a strategic effort by the Taiwanese government to establish the biotech industry as a primary growth engine. By scaling the production of cells used in regenerative therapies, Taiwan aims to meet rising domestic and international demand for advanced medical treatments [1, 2].

The new plant is a 10-story building designed for high-volume contract manufacturing [2]. The facility is intended to streamline the creation of cellular products, reducing the time and cost associated with producing the biological materials necessary for regenerative medicine.

Taiwanese authorities attended the opening ceremony to signal their support for the sector. The government has identified the bio-industry as a key area for economic expansion, providing the support necessary for companies like Locus Cell to build large-scale infrastructure [1, 2].

Company officials said the facility is intended to serve as a foundational pillar for the region's medical technology. A representative from Locus Cell said, "In the future, we want to make this an important hub like TSMC" [1].

The facility's scale and specialization are intended to position Taiwan as a central provider of cellular therapies in the Asia-Pacific region. By leveraging the existing industrial ecosystem in Hsinchu County, the plant integrates high-tech manufacturing with biological research to accelerate the delivery of cell-based therapies to patients [1, 2].

“Asia's largest cell mass-production facility”

This development signals Taiwan's ambition to diversify its high-tech economy beyond semiconductors. By explicitly comparing the facility to TSMC, Locus Cell and the Taiwanese government are attempting to apply the 'silicon shield' model of global indispensability to the biotech sector, aiming to dominate the supply chain for regenerative medicine in Asia.